US FDA approves Pfizer’s migraine nasal spray Zavzpret
Pharmaceutical Technology
MARCH 10, 2023
The company stated that the regulatory approval expands its migraine portfolio, which includes oral therapy for acute and preventive treatment. The regulator granted the approval based on two pivotal placebo-controlled, double-blind, randomised trials. The company expects to launch Zavzpret in pharmacies in July.
Let's personalize your content